FY23 consensus $4.25. Revises FY23 service revenue view to $2.254B-$2.274B from $2.244B-$2.274B, consensus $2.26B. Adjusted EBITDA is anticipated to be in the range of $235M-$245M.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMED:
- Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care
- AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE
- Amedisys initiated with a Neutral at Cantor Fitzgerald
- Amedisys price target lowered to $115 from $130 at Truist
- Amedisys to participate in a conference call with Jefferies
